Guest guest Posted March 3, 2011 Report Share Posted March 3, 2011 By inhibiting the protein with a drug, researchers can reduce the growth of the liquid tumor in test tubes by about 50 percent. The direction that the researchers aim toward is looking at these blood-born cancers for the expression of various proteins that are related to a subject called angiogenesis - growth of new blood vessels. " Now we are ready to take it to the next step and begin looking at certain treatment options that are directed against these growth factors as well as the process of angiogenesis, " said Dr. Edgar Bellamy, the lead researcher in the study. " It may give us another tool to fight these particular types of cancer. " Beginning May 1, UA assistant professor of medicine Dr. Alison Stopeck will oversee the testing of VEGF inhibitors on cancer patients who have non-Hodgkin's lymphoma. She will check whether the patients get well and whether the anti-angiogenic treatment is non-toxic. The discovery, which was published in the scientific journal Blood this month, was the result of two years of work studying angiogenesis. The work has involved three different labs and eight researchers, one of whom is a medical student who battled a potential cancer himself while he worked on the project. Angiogenesis - the creation of new blood vessels that tumors rely on to grow and spread - has been a widely-studied subject in cancer over the past decade. " Almost every tumor imaginable has this process turned on, so there is a tremendous excitement in this area right now in terms of therapeutic potentials, " Bellamy said. Sorry, I lost this URL, too. FYI, Lottie Duthu Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.